OM:QLINEA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Q-linea AB (publ) researches, develops, manufactures, and sells instruments and consumables for infection diagnostics. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Q-linea's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QLINEA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-11.1%

QLINEA

1.4%

SE Medical Equipment

-0.6%

SE Market


1 Year Return

116.9%

QLINEA

24.0%

SE Medical Equipment

17.8%

SE Market

Return vs Industry: QLINEA exceeded the Swedish Medical Equipment industry which returned 24% over the past year.

Return vs Market: QLINEA exceeded the Swedish Market which returned 17.8% over the past year.


Shareholder returns

QLINEAIndustryMarket
7 Day-11.1%1.4%-0.6%
30 Day3.9%4.6%1.0%
90 Day44.6%10.6%6.7%
1 Year116.9%116.9%25.8%24.0%20.0%17.8%
3 Yearn/a79.0%58.3%35.0%20.4%
5 Yearn/a79.4%48.6%64.4%32.3%

Price Volatility Vs. Market

How volatile is Q-linea's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Q-linea undervalued compared to its fair value and its price relative to the market?

8.23x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate QLINEA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate QLINEA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: QLINEA is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.

PE vs Market: QLINEA is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QLINEA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QLINEA is overvalued based on its PB Ratio (8.2x) compared to the SE Medical Equipment industry average (5.3x).


Next Steps

Future Growth

How is Q-linea forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

18.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: QLINEA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: QLINEA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: QLINEA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: QLINEA's revenue (64.2% per year) is forecast to grow faster than the Swedish market (3% per year).

High Growth Revenue: QLINEA's revenue (64.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: QLINEA is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Q-linea performed over the past 5 years?

-32.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QLINEA is currently unprofitable.

Growing Profit Margin: QLINEA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: QLINEA is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.

Accelerating Growth: Unable to compare QLINEA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: QLINEA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).


Return on Equity

High ROE: QLINEA has a negative Return on Equity (-43.49%), as it is currently unprofitable.


Next Steps

Financial Health

How is Q-linea's financial position?


Financial Position Analysis

Short Term Liabilities: QLINEA's short term assets (SEK396.2M) exceed its short term liabilities (SEK32.7M).

Long Term Liabilities: QLINEA's short term assets (SEK396.2M) exceed its long term liabilities (SEK171.0K).


Debt to Equity History and Analysis

Debt Level: QLINEA's debt to equity ratio (0.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if QLINEA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: QLINEA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: QLINEA has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 35.2% each year.


Next Steps

Dividend

What is Q-linea current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QLINEA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QLINEA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QLINEA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QLINEA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QLINEA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure


CEO

Jonas Jarvius (49 yo)

12.75yrs

Tenure

kr4,207,000

Compensation

Dr. Jonas Jarvius, Ph.D serves as the Chief Executive Officer and President of Q-linea AB. Dr. Jarvius served as Director at QuiaPEG Pharmaceuticals Holding AB (publ) since 2019 until 2020. Dr. Jarvius ser ...


CEO Compensation Analysis

Compensation vs Market: Jonas's total compensation ($USD475.90K) is about average for companies of similar size in the Swedish market ($USD491.17K).

Compensation vs Earnings: Jonas's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jonas Jarvius
CEO & President12.75yrskr4.21m1.34%
SEK 53.4m
Anders Lundin
Chief Financial Officer2.75yrsno data0.054%
SEK 2.2m
Nils Kristensen
Chief Operating Officer3.75yrsno data0.0016%
SEK 64.9k
Charlotta Göransson
Sales & Marketing Director0.75yrno data0.0016%
SEK 64.9k
Tiziana Di Martino
Chief Medical Officer1.25yrsno datano data
Thomas Fritz
Chief Commercial Officer1.08yrsno data0.017%
SEK 663.7k
Mats Gullberg
VP & Research Directorno datano data0.036%
SEK 1.4m

2.0yrs

Average Tenure

52.5yo

Average Age

Experienced Management: QLINEA's management team is considered experienced (2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Marcus Storch
Independent Director2.75yrskr155.00kno data
Hans Johansson
Independent Director2.75yrskr155.00k0.022%
SEK 867.7k
Per-Olof Wallstrom
Independent Director2.75yrskr185.00k0.019%
SEK 759.3k
Marianne Hansson
Independent Director2.75yrskr225.00k0.011%
SEK 455.4k
Mats Nilsson
Director12.75yrskr155.00k1.64%
SEK 65.5m
Erika Eriksson
Independent Chairperson2.75yrsno datano data
Mario Gualano
Director0.42yrno datano data

2.8yrs

Average Tenure

62yo

Average Age

Experienced Board: QLINEA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.3%.


Top Shareholders

Company Information

Q-linea AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Q-linea AB (publ)
  • Ticker: QLINEA
  • Exchange: OM
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr3.984b
  • Shares outstanding: 27.01m
  • Website: https://www.qlinea.com

Number of Employees


Location

  • Q-linea AB (publ)
  • Dag Hammarskjölds väg 52 A
  • Uppsala
  • Uppsala County
  • 752 37
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QLINEAOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKDec 2018
3F8DB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2018
QLINESBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBSEKDec 2018

Biography

Q-linea AB (publ) researches, develops, manufactures, and sells instruments and consumables for infection diagnostics. It offers inventive systems for in vitro diagnostics systems for infectious diseases. ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/18 22:23
End of Day Share Price2020/10/16 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.